Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.
Advertisement

Related Content

Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
Vicept Acquired By Allergan For $75M Upfront
The Number One Question For Valeant: What Next?
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard
Valeant Readies For More Expansion In 2011
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS072497

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel